Vistagen Therapeutics (NASDAQ:VTGN - Get Free Report) is expected to release its Q4 2025 earnings data before the market opens on Tuesday, June 10th. Analysts expect Vistagen Therapeutics to post earnings of ($0.53) per share and revenue of $0.18 million for the quarter.
Vistagen Therapeutics Stock Performance
Shares of NASDAQ VTGN remained flat at $2.39 during midday trading on Wednesday. 47,225 shares of the stock were exchanged, compared to its average volume of 171,689. The firm has a market cap of $68.98 million, a P/E ratio of -1.61 and a beta of 0.67. The stock's fifty day moving average price is $2.30 and its 200 day moving average price is $2.60. Vistagen Therapeutics has a 52 week low of $1.90 and a 52 week high of $4.21.
Institutional Investors Weigh In On Vistagen Therapeutics
A hedge fund recently bought a new stake in Vistagen Therapeutics stock. Cubist Systematic Strategies LLC purchased a new position in shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 10,088 shares of the company's stock, valued at approximately $25,000. 78.39% of the stock is owned by institutional investors.
Vistagen Therapeutics Company Profile
(
Get Free Report)
Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.
Read More
Before you consider Vistagen Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vistagen Therapeutics wasn't on the list.
While Vistagen Therapeutics currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
